Papp L Roy & Associates continued to hold its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,278 shares of the medical research company’s stock at the close of the second quarter. Papp L Roy & Associates’ holdings in Amgen were worth $1,598,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Univest Corp of Pennsylvania raised its position in shares of Amgen by 6.0% in the 2nd quarter. Univest Corp of Pennsylvania now owns 25,347 shares of the medical research company’s stock worth $4,366,000 after buying an additional 1,445 shares during the period. Brave Asset Management Inc. raised its position in shares of Amgen by 38.1% in the 2nd quarter. Brave Asset Management Inc. now owns 9,943 shares of the medical research company’s stock worth $1,712,000 after buying an additional 2,744 shares during the period. ST Germain D J Co. Inc. raised its position in shares of Amgen by 1.1% in the 2nd quarter. ST Germain D J Co. Inc. now owns 95,713 shares of the medical research company’s stock worth $16,485,000 after buying an additional 1,005 shares during the period. Gamble Jones Investment Counsel raised its position in shares of Amgen by 13.9% in the 2nd quarter. Gamble Jones Investment Counsel now owns 36,320 shares of the medical research company’s stock worth $6,255,000 after buying an additional 4,424 shares during the period. Finally, Ronald Blue & Co. LLC purchased a new position in shares of Amgen in the 2nd quarter worth $221,000. 78.10% of the stock is currently owned by institutional investors and hedge funds.
Shares of Amgen Inc. (NASDAQ AMGN) opened at 184.15 on Thursday. The company has a market capitalization of $134.37 billion, a PE ratio of 16.77 and a beta of 1.36. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. The company has a 50-day moving average of $182.76 and a 200-day moving average of $170.66.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. During the same quarter last year, the firm posted $2.84 EPS. The company’s quarterly revenue was up 2.1% on a year-over-year basis. On average, analysts anticipate that Amgen Inc. will post $12.58 earnings per share for the current year.
Several brokerages recently weighed in on AMGN. Royal Bank Of Canada began coverage on Amgen in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 target price on the stock. Bank of America Corporation raised their price objective on Amgen to $210.00 and gave the company a “buy” rating in a research report on Thursday, October 5th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research report on Friday, October 6th. Morgan Stanley reissued an “overweight” rating and issued a $196.00 price objective (up from $189.00) on shares of Amgen in a research report on Friday, October 6th. Finally, Mizuho reissued a “buy” rating and issued a $198.00 price objective on shares of Amgen in a research report on Friday, October 6th. Ten equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Amgen has an average rating of “Buy” and a consensus target price of $189.99.
In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.19% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
What are top analysts saying about Amgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen Inc. and related companies.